Negative Impact of ST-Segment Elevation Myocardial Infarction and Morphine Dose on Ticagrelor Uptake and Pharmacodynamics: A Population PK/PD Analysis of Pooled Individual Participant Data

[1]  C. Haynes,et al.  Characterization of the Presence and Function of Platelet Opioid Receptors , 2021, ACS measurement science Au.

[2]  J. van der Linden,et al.  Impact of morphine dose on ticagrelor uptake and platelet inhibition in patients with ST-segment elevation myocardial infarction – A substudy from the prospective randomized MOVEMENT trial , 2021, Thrombosis Update.

[3]  Ò. Miró,et al.  Antithrombotic and anticoagulation therapies in cardiogenic shock: a critical review of the published literature , 2021, ESC heart failure.

[4]  K. Kubica,et al.  Pharmacokinetic Modeling of Morphine’s Effect on Plasma Concentrations of Ticagrelor and Its Metabolite in Healthy Volunteers , 2021, Frontiers in Physiology.

[5]  Ying Zhang,et al.  Effects of morphine on P2Y12 platelet inhibitors in patients with acute myocardial infarction: A meta-analysis. , 2020, The American journal of emergency medicine.

[6]  G. Filippatos,et al.  Acute coronary syndromes and acute heart failure: a diagnostic dilemma and high‐risk combination. A statement from the Acute Heart Failure Committee of the Heart Failure Association of the European Society of Cardiology , 2020, European journal of heart failure.

[7]  A. Harroche,et al.  Real Life Population Pharmacokinetics Modelling of Eight Factors VIII in Patients with Severe Haemophilia A: Is It Always Relevant to Switch to an Extended Half-Life? , 2020, Pharmaceutics.

[8]  J. Siller-Matula,et al.  Impact of Preadmission Morphine on Reinfarction in Patients With ST‐Elevation Myocardial Infarction Treated With Percutaneous Coronary Intervention: A Meta‐Analysis , 2020, Clinical pharmacology and therapeutics.

[9]  W. Chan,et al.  Association of periprocedural intravenous morphine use on clinical outcomes in ST‐elevation myocardial infarction (STEMI) treated by primary percutaneous coronary intervention: Systematic review and meta‐analysis , 2020, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[10]  E. Coomes,et al.  Chewed or Crushed Administration of Adenosine Diphosphate Receptor Inhibitors in Acute Coronary Syndromes: a Systematic Review and Meta-analysis of Randomized Controlled Trials , 2019, Cardiovascular Drugs and Therapy.

[11]  Hongwei Wu,et al.  Prediction of Ticagrelor and its Active Metabolite in Liver Cirrhosis Populations Using a Physiologically Based Pharmacokinetic Model Involving Pharmacodynamics. , 2019, Journal of pharmaceutical sciences.

[12]  M. Åstrand,et al.  Population Pharmacokinetics/Pharmacodynamics of Ticagrelor in Children with Sickle Cell Disease , 2019, Clinical Pharmacokinetics.

[13]  E. Navarese,et al.  Determinants of high platelet reactivity in patients with acute coronary syndromes treated with ticagrelor , 2019, Scientific Reports.

[14]  Abdur Rahman Khan,et al.  Effect of morphine use on oral P2Y12 platelet inhibitors in acute myocardial infarction: Meta-analysis , 2019, Indian heart journal.

[15]  G. Duarte,et al.  Morphine in acute coronary syndrome: systematic review and meta-analysis , 2019, BMJ Open.

[16]  Marc P. Bonaca,et al.  Pharmacokinetic–pharmacodynamic modelling of platelet response to ticagrelor in stable coronary artery disease and prior myocardial infarction patients , 2018, British journal of clinical pharmacology.

[17]  L. Been,et al.  Effects of the Peripheral Opioid Receptor Antagonist Methylnaltrexone on the PK and PD Profiles of Ticagrelor in Patients With Coronary Artery Disease Treated With Morphine. , 2019, JACC. Cardiovascular interventions.

[18]  M. Marszałł,et al.  METoclopramide Administration as a Strategy to Overcome MORPHine-ticagrelOr Interaction in PatientS with Unstable Angina PectorIS—The METAMORPHOSIS Trial , 2018, Thrombosis and Haemostasis.

[19]  Z. Djerada,et al.  Alteration in the availability of epoxyeicosatrienoic acids contributes with NO to the development of endothelial dysfunction in conduit arteries during aging. , 2018, Atherosclerosis.

[20]  B. Jilma,et al.  Morphine Interaction with Aspirin: a Double-Blind, Crossover Trial in Healthy Volunteers , 2018, The Journal of Pharmacology and Experimental Therapeutics.

[21]  X. Tian,et al.  Population pharmacokinetics and pharmacodynamics of ticagrelor and AR-C124910XX in Chinese healthy male subjects , 2018, European Journal of Clinical Pharmacology.

[22]  D. Guerrot,et al.  Population Pharmacokinetic-Pharmacodynamic Modeling of Ropivacaine in Spinal Anesthesia , 2018, Clinical Pharmacokinetics.

[23]  P. Kolh,et al.  [2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS.] , 2018, Kardiologia polska.

[24]  M. Marszałł,et al.  Comparison of bioavailability and antiplatelet action of ticagrelor in patients with ST-elevation myocardial infarction and non-ST-elevation myocardial infarction: A prospective, observational, single-centre study , 2017, PloS one.

[25]  J. van der Linden,et al.  Ticagrelor pharmacokinetics and pharmacodynamics in patients with NSTEMI after a 180-mg loading dose , 2017, Platelets.

[26]  Marc Lavielle,et al.  Enhanced Method for Diagnosing Pharmacometric Models: Random Sampling from Conditional Distributions , 2016, Pharmaceutical Research.

[27]  B. Jilma,et al.  Morphine decreases ticagrelor concentrations but not its antiplatelet effects: a randomized trial in healthy volunteers , 2016, European journal of clinical investigation.

[28]  M. Marszałł,et al.  Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: the randomized, double-blind, placebo-controlled IMPRESSION trial , 2015, European heart journal.

[29]  D. Angiolillo,et al.  Impact of Escalating Loading Dose Regimens of Ticagrelor in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: Results of a Prospective Randomized Pharmacokinetic and Pharmacodynamic Investigation. , 2015, JACC. Cardiovascular interventions.

[30]  M. Price,et al.  Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention. , 2015, European heart journal.

[31]  J. Dillinger,et al.  Ticagrelor effectiveness overestimated by VASP index: platelet inhibition by ticagrelor versus prasugrel in acute coronary syndrome patients according to platelet function tests. , 2014, International journal of cardiology.

[32]  P. Dobesh,et al.  Ticagrelor: Pharmacokinetics, Pharmacodynamics, Clinical Efficacy, and Safety , 2014, Pharmacotherapy.

[33]  Deepak L. Bhatt,et al.  Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. , 2013, Journal of the American College of Cardiology.

[34]  R. Abbate,et al.  Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study. , 2013, Journal of the American College of Cardiology.

[35]  F. Crea,et al.  Evidence of increased platelet reactivity in the first six months after acute ST segment elevation myocardial infarction. , 2011, Thrombosis research.

[36]  P. Gurbel,et al.  The effect of ticagrelor versus clopidogrel on high on-treatment platelet reactivity: combined analysis of the ONSET/OFFSET and RESPOND studies. , 2011, American heart journal.

[37]  S. Oliver,et al.  Absorption, Distribution, Metabolism, and Excretion of Ticagrelor in Healthy Subjects , 2010, Drug Metabolism and Disposition.

[38]  P. Holzer.  Opioid receptors in the gastrointestinal tract , 2009, Regulatory Peptides.

[39]  F. Verheugt,et al.  Impaired bioavailability of clopidogrel in patients with a ST-segment elevation myocardial infarction. , 2008, Thrombosis research.

[40]  C. Cannon,et al.  Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial. , 2007, Journal of the American College of Cardiology.

[41]  Mats O. Karlsson,et al.  Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies , 2007, Journal of Pharmacokinetics and Pharmacodynamics.

[42]  P. Tothill,et al.  Inhibition of gastric emptying and drug absorption by narcotic analgesics. , 1975, British journal of clinical pharmacology.